2020 Trends In Pharma Asset Licensing And Deal Terms: A Survey Of Key Decision-Makers Lain Anderson TJ Bilodeau Read more
Related Practice Life Sciences & Pharma In this article, we describe some key drivers of asset value, as well as areas of alignment and divergence between parties on deal expectations. 01052021090143
Video / Webinar Healthcare Services Australia's Clinical Trials: Innovation and Growth February 24, 2025
Executive Insights MedTech Opportunity to Build a Billion-Dollar-Revenue MedTech Platform in India February 4, 2025
Executive Insights Life Sciences & Pharma Redefining Biopharma R&D Productivity: New Insights and Strategies January 9, 2025
Executive Insights Life Sciences & Pharma Preparing for Innovation: A Maturity Framework for Artificial Intelligence in Life… August 2, 2024
Article Mergers & Acquisitions Mergers and Acquisitions in Latin America: Evolution and Prospects May 13, 2024